Artificial intelligence+medical treatment is an empowering phenomenon of artificial intelligence technology to application scenarios in medical-related fields, that is, using the most advanced artificial intelligence technology to realize the informationization between patients and medical workers, medical institutions and medical equipment. It can be understood as applying artificial intelligence technology and big data services to the medical industry through infrastructure construction and data collection, improving the diagnostic efficiency and service quality of the medical industry, and better solving the problems of shortage of medical resources and aging population.
Policy blessing, technical iteration, and market demand drive, AI+ medical care has ushered in rapid development.
2020 is a turning point in the AI+ medical industry. On the one hand, the audit of three types of AI medical devices has made the AI medical imaging industry from "application landing" to "commercialization", which has been bothering it for many years. On the other hand, the epidemic has accelerated the initiative and intelligent reconstruction of hospitals and enterprises. According to iResearch's China AI+ Medical Industry Research Report, the CAGR (Compound Growth Rate) will reach 5 1.9% in 2020-2022, and it is estimated that the AI+ medical market will exceed 7 billion yuan in 2022.
In addition, the policy dividend has also greatly promoted the application practice of AI+ medical care.
AI+ medical track is hot. From 2020 to now, the financing amount is nearly 20 billion yuan.
According to the data of China Commercial Industry Research Institute, AI+ medical care has accounted for 18.9% of the artificial intelligence market in 2020. According to IDC statistics, by 2025, the total market value of artificial intelligence applications will reach $654.38+027 billion, of which the application of artificial intelligence in the medical industry will account for one fifth of the market size, that is, $25 billion. In all applications of artificial intelligence, medical treatment ranks first.
AI+ medical imaging products and enterprises are constantly emerging. According to the incomplete statistics of Tianyancha, since 2020, there have been 89 financing incidents in the domestic AI+ medical field, with a total financing amount of 654.38+0.75 billion yuan, of which medical imaging accounts for about 654.38+0/3 of the total financing amount.
According to the research of Tianyancha Data Research Institute, from the financing rounds in the past two years, more than 60% of enterprises are in the A and B rounds, and these enterprises have begun to enter a mature development stage. Enterprises whose product technology is recognized by the market and whose business model is mature are also more likely to be favored by capital. Enterprises have also increased technology research and development, cultivated competitive advantages through innovation, and accelerated the pace of development.
AI+ has a wide range of medical applications.
At present, AI+ medical care in China is mainly used in five fields: medical imaging, auxiliary medical care, drug research and development, health management and disease prediction.
AI medical imaging. It has the characteristics of high speed, high stability and low cost. With the development of medical image big data and image recognition technology, medical image has become the most mature field of artificial intelligence and medical treatment in China. The AI medical imaging industry is outstanding, with mature products in the fields of tuberculosis, fundus, breast cancer and cervical cancer.
According to the survey data of Sky Eye, at present, there are more than 20,000 enterprises operating, surviving, moving in or moving out in China, and more than 50% of them were established within five years. In terms of geographical distribution, Guangdong has the largest number of medical imaging enterprises, exceeding 3,000, accounting for 13% of the country.
The combination of artificial intelligence and medical treatment makes traditional medical treatment enter the era of intelligent medical treatment, and the ability of artificial intelligence (AI) medical image-aided diagnosis is becoming more and more obvious. From the patent application data, from 2065,438+065,438+0 to 2020, there are more than 7,000 pieces of patent application information, and the number is increasing year by year. Among the types of patents, invention patents account for the largest proportion, reaching 53.73%, followed by utility models, accounting for 38.46%.
AI auxiliary medical care. In terms of auxiliary diagnosis, Dr. Watson's platform, for example, can synthesize all kinds of information of patients in a short time, and give accurate diagnosis results and treatment plans with millions of data. In the auxiliary surgery, take Da Vinci robot as an example. It is a man-machine cooperative robot. During the operation, doctors can use the mechanical arm thousands of miles away for real-time and accurate surgical assistance.
At present, there are more than 1 10000 enterprises related to medical diagnosis in China, and more than 80% of them were established within five years. Among them, in 2020 alone, there will be more than 30,000 newly registered enterprises, with a growth rate of 63%. In terms of geographical distribution, Guangdong has the largest number of AI-aided diagnosis enterprises, exceeding 30,000, accounting for 30% of the country.
Artificial intelligence drug research and development. Domestic research and development of new drugs is mainly based on generic drugs and improved drugs, mainly because AI companies cooperate with pharmaceutical companies to develop new drugs. The complete process of drug research and development includes target screening, drug discovery, clinical trials and so on. With the application of big data and artificial intelligence in scientific research, drug research and development will become more accurate and convenient, and efficiently solve the problems of long cycle, high cost and low success rate.
At present, there are more than 60,000 pharmaceutical R&D-related enterprises in China, 50% of which were established in 1 year. Among them, in 2020 alone, there will be more than 20,000 newly registered enterprises, with the growth rate approaching 100%. In terms of geographical distribution, the number of R&D enterprises in Guangdong is the largest, exceeding 1. 1 10,000, accounting for 18% of the whole country.
AI health management. The product form is mainly smart wearable devices. After the scope of 20 19 medical AI was extended to the field of health care, domestic wearable devices were more and more widely used in medical scenes. Through the intelligent analysis of health big data, individuals or enterprises can be helped to manage their own health in a targeted manner. Through long-term real-time monitoring and multi-dimensional data management and analysis, passive disease treatment can be transformed into active health monitoring.
There are more than 1.5 million wearable device-related enterprises in China, including 368 high-tech enterprises, accounting for 2.4%. In terms of geographical distribution, Guangdong has the largest number of wearable device-related enterprises, exceeding1.2000. From the perspective of patent distribution, the patent types of wearable device-related enterprises are mainly inventions, accounting for 46.2%. In addition, utility model and design patents account for 34.0% and 19.8% respectively.
AI disease detection. Mainly concentrated in the field of genetic testing. Advantages: First, China has a large number of data samples. Computers need a lot of data and constantly train algorithms. Many countries do not have such a large population base, and the amount of disease data is limited. Second, China has broad application scenarios. With a large number of patients and relatively few doctors, there is a great demand for remote and artificial intelligence diagnosis in China.
At present, there are more than 5,800 enterprises related to genetic testing in China, including high-tech enterprises 190, accounting for 3.2%. In terms of geographical distribution, Guangdong has the largest number of enterprises related to genetic testing, with nearly 1.300, accounting for 22%. From the perspective of patent distribution, the patent types of genetic testing related enterprises are mainly inventions, accounting for 72.4%. In addition, utility model and design patents account for 24.4 1% and 3. 19% respectively.
Technology and application dual-engine drive AI+ medical empowerment smart life is close at hand.
Judging from the development trend of AI+ medical industry, with the development of artificial intelligence, mobile Internet, Internet of Things, big data and big data security, all aspects of health whole process management will become more and more intelligent, and precision medical care will become more and more personalized and individualized.
First of all, AI and big data should establish an open operation system with manageable, controllable and traceable health care data, and promote the circulation service of health care big data. On the basis of exploring new technologies such as medical data privacy computing and artificial intelligence, innovative application integration is carried out in the field of auxiliary diagnosis and treatment in the medical industry. The empowerment of privacy computing technology can realize the real privacy protection of medical data and maximize the value of data. For example, Huakong Qingjiao, which focuses on privacy protection and data circulation technology, has conducted AI model training analysis on medical image data, verifying the consistency between the training results and the plaintext results.
Secondly, in terms of the application maturity of AI in the medical field, medical imaging, as a hot investment and financing track in the AI+ medical field, has more and more subdivided application scenarios. The application of AI+CT images in intelligent aided diagnosis of cardiovascular diseases, nervous system diseases, brain diseases, fundus diseases and lung diseases has matured in China. For example, pension enterprises integrate AI fundus screening, millimeter-wave radar and high-sensitivity biochip technology to create black technology products suitable for the elderly, such as fundus artificial intelligence chronic disease detector, which can screen out 30 kinds of health diseases within 3 minutes and get a physical examination report generated according to automatic algorithm.
In the future, with the excellent algorithms and big data analysis of AI+ Medical, we will gradually break through the data barriers of all service ports of relevant service platforms, and achieve perfect landing in all core application scenarios, and finally improve the overall medical level of China.